| 1. |
|
|
| 2. |
- Andersson, Sören, 1957-, et al.
(författare)
-
CHIMERIC MOMP ANTIGEN
- 2015
-
Patent (populärvet., debatt m.m.)
|
|
| 3. |
- Andersson, Sören, 1957-, et al.
(författare)
-
Chimeric MOMP antigen
- 2014
-
Patent (populärvet., debatt m.m.)abstract
- The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.
|
|
| 4. |
- Löfstedt, Christer, et al.
(författare)
-
METHODS OF PRODUCING INSECT PHEROMONES
- 2021
-
Patent (övrigt vetenskapligt/konstnärligt)abstract
- The present disclosure relates to methods of producing insect pheromone precursors and genetically modified plants capable of producing insect pheromone precursors. The genetically modified plants include a heterologous gene encoding at least one silencing suppressor protein and at least one enzyme selected from the group consisting of a fatty acyl desaturase, a fatty acyl elongase, a fatty acyl reductase, and an acyl-CoA oxidase.
|
|
| 5. |
- Eriksson, Leif A., 1964-, et al.
(författare)
-
Tetrazole derivatives as cytochrome p450 inhibitors
- 2019
-
Patent (populärvet., debatt m.m.)abstract
- According to the invention there is provided a compound of formula I, wherein R1 and R2 have meanings given in the description, which compounds are useful in the treatment of skin disorders and other diseases.
|
|
| 6. |
- Ahmadian, Afshin, et al.
(författare)
-
Method for amplification
- 2005
-
Patent (populärvet., debatt m.m.)abstract
- The invention refers to a method for multiplex amplification of at least one specific nucleic acid locus, comprising the steps of: providing at least one oligonucleotide probe pair that is designed so that the first and second probe of the pair anneal to a specific nucleic acid locus on a target molecule, in which pair the first probe has an extendable 3'-end, and a second probe has a 5'-end that is directly or indirectly labelled with a phosphate group; providing a target molecule comprising at least one specific nucleic acid locus; allowing the probe pair to anneal to the target molecule; allowing the 3'-end of the first probe to extend by influence of polymerase by adding a set of three different dNTPs; ligating the 3'-end of the extended first probe to the 5'-end of the second probe. Hereby, a method is provided which allows a high specificity for simultaneous amplification of several loci. Further, the invention involves a kit for use in the method of the invention.
|
|
| 7. |
- Gräslund, Torbjörn, et al.
(författare)
-
IGF-1R binding polypeptides and their use
- 2007
-
Patent (populärvet., debatt m.m.)abstract
- This invention relates to polypeptides which bind to IGF-1R and to applications of those polypeptides in medicine, veterinary medicine, diagnostics and imaging.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Lewensohn, Rolf, et al.
(författare)
-
S100a6 and/or s100a4 inhibitors for treating cancer
- 2008
-
Patent (populärvet., debatt m.m.)abstract
- Aspects of this invention relate to the fields of molecular biology and medicine. More specifically, disclosed herein are several approaches to provide subjects suffering from cancer with an inhibitor of S100A6 and/or S 100A4 alone or in combination with other cancer therapies so as to improve the cancer therapy and/or more efficiently treat cancer, in particular forms of cancer that are resistant to other therapies. Also disclosed herein are approaches for using S 100A6 and/or S 100A4 as a biomarker for metastases. Further, disclosed herein are approaches for using S 100A6 and/or S 100A4 as a biomarker for cancer therapies, in particular, as a biomarker to determine individual responses to cancer therapies. In addition, disclosed herein are approaches to identifying S 100A6 and/or S 100A4 inhibitors, for example, that act synergistically with a cancer therapy.
|
|
